0001562180-20-005001.txt : 20200706
0001562180-20-005001.hdr.sgml : 20200706
20200706175034
ACCESSION NUMBER: 0001562180-20-005001
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200701
FILED AS OF DATE: 20200706
DATE AS OF CHANGE: 20200706
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Llewelyn Linda
CENTRAL INDEX KEY: 0001780878
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38993
FILM NUMBER: 201014483
MAIL ADDRESS:
STREET 1: C/O HEALTH CATALYST, INC.
STREET 2: 3165 E. MILLROCK DRIVE #400
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Health Catalyst, Inc.
CENTRAL INDEX KEY: 0001636422
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ETC. [7370]
IRS NUMBER: 453337483
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3165 E. MILLROCK, SUITE 400
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84121
BUSINESS PHONE: 801-708-6800
MAIL ADDRESS:
STREET 1: 3165 E. MILLROCK, SUITE 400
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84121
FORMER COMPANY:
FORMER CONFORMED NAME: HQC Holdings, Inc.
DATE OF NAME CHANGE: 20150312
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2020-07-01
false
0001636422
Health Catalyst, Inc.
HCAT
0001780878
Llewelyn Linda
C/O HEALTH CATALYST, INC.
3165 MILLROCK DRIVE, #400
SALT LAKE CITY
UT
84121
false
true
false
false
Chief People Officer
Common Stock
2020-07-01
4
M
false
2242.00
10.80
A
27619.00
D
Common Stock
2020-07-01
4
S
false
1021.00
28.77
D
26598.00
D
Common Stock
2020-07-01
4
S
false
1221.00
29.97
D
25377.00
D
Stock Option (Right to Buy)
10.80
2020-07-01
4
M
false
2242.00
0.00
D
2028-09-27
Common Stock
2242.00
32439.00
D
The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on November 21, 2019, in accordance with Rule 10b5-1.
Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $28.52 to $29.42, inclusive.
Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $29.74 to $30.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (2) and (3).
25% of the 59,351 shares underlying the options vested in an annual installment on September 25, 2019 and the remaining balance vested or will vest in equal monthly installments until the option is vested in full on September 25, 2022.
/s/ Daniel Orenstein, as Attorney-in-Fact
2020-07-06